Shareholders approve 19.5M share increase to 2021 Equity Plan at annual meeting

Lineage Cell Therapeutics, Inc.

Shareholders approved amendment increasing common shares reserved under 2021 Equity Plan by 19,500,000.
All seven director nominees elected: Mulroy, Amin, Andrews, Russell, Bradsher, Culley, Jayasuriya.
Ratification of Baker Tilly as auditor for FY2025 received ~159M votes for, ~912K against.
Advisory say-on-pay approved with ~96M votes for, ~3.8M against, ~612K abstentions.
EIP Amendment approved with ~88.6M for, ~11.6M against, ~351K abstentions.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.